Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT05198960 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT05198960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05198960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Lead sponsor
University Hospital, Brest
Phase
Phase 3
Overall status
Recruiting
Start date
July 13, 2022
Completion date
July 13, 2027
Enrollment
1,308 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia, high-risk patients, jak2 v617f, polycythemia vera, prefibrotic/early primary myelofibrosis